HOME >> MEDICINE >> NEWS
Outsmarting cancer - new results from novel enzyme inhibitors

Smart drugs that can break the chain of command between enzymes and the genes involved in cell division and cell death are a new way forward in tackling breast cancer, according to Dr Stephen Johnston, a consultant oncologist from The Royal Marsden Hospital, London, UK.

Presenting results from the worlds first phase II trial of R115777 (Zarnestra) in breast cancer, Dr. Johnston said that among 41 women with advanced cancer who had previously undergone chemotherapy or hormone treatment, four had a partial response from the new drug and in a further six the disease had been stabilised over a prolonged period. Trials are now planned combining R115777 with chemotherapy or hormone therapy, as laboratory studies indicate that the new drug acts synergistically with conventional treatments to boost their effectiveness.

R115777 is one of a novel drug class called farnesyl transferase inhibitors, he told a news briefing at the 3rd European Breast Cancer Conference in Barcelona. Farnesyl transferase is an enzyme that enables a protein called Ras to function and signal correctly within the cell. Ras plays a prominent part in many types of tumours. Although it is rarely directly mutated in breast cancer, Ras often receives signals from growth factors that make it function in an abnormal way, promoting the growth of breast cancer cells. Interrupting the cellular signals by targeting Ras breaks the chain of command between the growth factors and the nucleus of the cell and appears to inhibit the growth of the cancer cells. In addition, several other proteins involved in cell growth and motility may also be farnesylated and so may also be targets for farnesyl transferase inhibitors.

Another key enzyme the 26S proteasome is also in the firing line for smart drugs. Proteasome is a protein complex that modulates the behaviour of cells during the cell cycle. It regulates the levels of key proteins that control the fine balance between normal cell division
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
34-93-3644487
Federation of European Cancer Societies
21-Mar-2002


Page: 1 2

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. International breast cancer prevention study launches in the United States and Canada
3. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
4. Cultural and social factors influence prostate cancer treatment
5. Primary care office strategies may increase colon cancer screening
6. Benefits of lung cancer screening with CT questioned
7. Three-year cervical cancer screening recommendations may be applicable for certain women with HIV
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. African-American women with endometrial cancer have more aggressive cancer than Caucasian women
10. Employment prospects good for most cancer survivors -- but not all
11. New colorectal cancer screening recommendations for African Americans

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Outsmarting cancer new results from novel enzyme inhibitors

(Date:6/19/2013)... study led by researchers at The University of Texas ... to show remarkable promise for the treatment of relapsed ... recent interim findings of the 18-center Phase 2 study ... of Medicine . Previous interim findings were presented in ... Annual Meeting and Exposition. , Unprecedented results, ...
(Date:6/19/2013)... In a study published in the June 19 online ... team led by researchers from the University of California, ... cellular events that take place when cardiac regeneration occurs ... provide evidence that various cell lines in the heart ... cell types, than previously thought. , More importantly, the ...
(Date:6/19/2013)... A new understanding of the genetic process that ... of potentially dangerous lesions for some women, and also ... therapies in certain cases suggesting they could actually ... The analysis provides a clearer picture of the chromosomal ... papillomavirus sometimes leads to chronic infection and, in less ...
(Date:6/19/2013)... Iowa study reveals significant disparities between minority and ... abuse treatment programs. Moreover, these disparities vary widely ... suggest that for most states there,s something amiss," ... and biostatistics. "There are strong racial and ethnic ... substance abuse treatment programs successfully, and those disparities ...
(Date:6/19/2013)... 19, 2013) In early April, senior leaders from ... Hartford, Connecticut, to discuss one question: how can first ... , The preliminary results of this discussion are ... Events: The Hartford Consensus ," a concept paper published ... Journal of Trauma and Acute Care Surgery , ...
Breaking Medicine News(10 mins):Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
(Date:6/19/2013)... BETHESDA, Md. , June 19, 2013 /PRNewswire/ -- ... "Company"), an American healthcare company providing services in ... of United Family Healthcare, a network of private ... official opening of its Beijing United Family Rehabilitation ... development projects of the United Family Healthcare ("UFH") ...
(Date:6/19/2013)... -- BD Biosciences, a segment of BD (Becton, Dickinson and ... technology company, today announced the launch of the BD ... of high-performance research flow cytometers. The BD ... most compact footprint in its class at just 30" x ... (76.2 cm). Recognizing that space is a valuable commodity in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
Cached News: